Washington, D.C., April 2, 2026 U.S. President Donald Trump has imposed tariffs of up to 100 percent on imported patented medicines, aiming to boost domestic production and reduce reliance on foreign pharmaceutical suppliers. The new tariffs, which will take effect in 120 days for large companies and 180 days for smaller firms, target patented drugs entering the U.S. market. Swiss pharmaceutical exports will face a lower rate of 15 percent under the policy. The White House stated the move is designed to strengthen domestic manufacturing and secure supply chains. "Companies can reduce or avoid tariffs by building production capacity in the USA and making price agreements with the authorities," according to the administration’s announcement. At least 16 major pharmaceutical firms have already reached agreements with the U.S. government to comply with the new measures. The administration did not disclose which companies were involved or the terms of the deals. No immediate reactions from foreign governments or industry groups were included in the verified facts. The policy marks the latest in a series of trade measures by the Trump administration targeting critical sectors. The announcement follows years of U.S. efforts to reshore pharmaceutical production, particularly after supply chain disruptions during the COVID-19 pandemic highlighted dependencies on overseas drug manufacturing.